Hyderabad: People in Hyderabad and other urban hubs of Telangana, as well as in the southern states of the country, are ...

LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders Lexicon has earned a second of three potential ...

EMBC to acquire Owen Mumford for up to $199.4M, aiming to expand beyond diabetes into high-value drug delivery and boost long ...

Analysis of over 750,000 pregnancies reveals that GLP-1 weight loss drugs are safe in early pregnancy, but pose risks when used for diabetes.

Excess fat stored around the waist is more strongly associated with heart failure risk than body mass index (BMI), according ...